Bar, J., Mansfield, A. S., Daaboul, N., Horinouchi, H., Baijal, S., Lu, S., Ratajczak, C., Ohrling, K., Patel, S. A., Woll, K., Mhaske, P., Sun, Y., Zhang, J., Verma, M., Zhao, W., Roberts-Rapp, L., Zhang, N., Ansell, P., Navas, T., Camidge, D. R. (2026). Impactof
                    <i>MET</i>
                    amplification (amp) on telisotuzumab vedotin (Teliso-V) efficacy and safety in 2L+ non-squamous (NSQ)
                    <i>EGFR</i>
                    wild-type (WT) NSCLC with c-Met protein overexpression (OE).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8524